Skip to main content

Year: 2025

Diversified Energy Achieves Strong Quarterly Results and Raises 2025 Financial Guidance

Robust Cash Flow Generation Driven by Increased Scale, Operational Synergies, and Asset Optimization Strategy Improved Leverage Year-to-Date by Approximately 20% and Within Target Range Returned a Record ~$146 million to Shareholders Through Dividends and Repurchases Year to Date, Further Validating Cash Generative Business Model Diversified Energy Company PLC (“Diversified”, “DEC” or the “Company”) (LSE: DEC, NYSE: DEC) is pleased to announce the following operational and financial results for the quarter ended September 30, 2025. Third Quarter 2025 ResultsProduction exit rate(a): 1,144 MMcfepd (191 Mboepd)Average production: 1,127 MMcfepd (188 Mboepd) Production volume mix (natural gas, NGLs, oil): 74% / 13% / 13%Total Revenue (including settled hedges)(d): $500 million Operating Cash Flow: ~$166 million Adjusted EBITDA(b):...

Continue reading

Upwork Reports Third Quarter 2025 Financial Results

Achieves record quarterly revenue of $201.7 million in Q3 2025 Generates GAAP net income of $29.3 million and record adjusted EBITDA of $59.6 million, resulting in 15% profit margin and all-time high 30% adjusted EBITDA margin Raises FY2025 revenue and adjusted EBITDA guidance PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today announced its financial results for the third quarter of 2025. “The third quarter marked the start of the next chapter for Upwork. As we build the world’s human and AI-powered work marketplace, we’re driving phenomenal user productivity and engagement, resulting in a return to positive GSV growth,” said Hayden Brown, president and CEO, Upwork Inc. “We are executing with speed and precision across our growth levers of AI,...

Continue reading

Bogota Financial Corp. Reports Results for the Three and Nine Months Ended September 30, 2025

TEANECK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) — Bogota Financial Corp. (NASDAQ: BSBK) (the “Company”), the holding company for Bogota Savings Bank (the “Bank”), reported net income for the three months ended September 30, 2025 of $455,000, or $0.04 per basic and diluted share, compared to a net loss of $367,000, or $0.03 per basic and diluted share, for the comparable prior year period. The Company reported net income for the nine months ended September 30, 2025 of $1.4 million, or $0.11 per basic and diluted share, compared to a net loss of $1.2 million, or $0.10 per basic and diluted share, for the comparable prior year period. Income for the nine months ended September 30, 2025 included a one-time death benefit from a bank-owned life insurance policy related to a former employee of approximately $543,000. On August 12, 2025,...

Continue reading

UFP Technologies Announces Strong Q3 2025 Results

NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per diluted common share outstanding compared to net income of $42.6 million or $5.49 per diluted common share outstanding for the same period in 2024....

Continue reading

The Ensign Group Reports Third Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance

Conference Call and Webcast scheduled for tomorrow, November 4, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the third quarter of 2025, reporting GAAP diluted earnings per share of $1.42 and adjusted earnings per share(1) of $1.64, both for the quarter ended September 30, 2025. Highlights Include:GAAP diluted earnings per share for the quarter was $1.42, an increase of 6.0% over the prior year quarter, and adjusted diluted earnings per share(1) for the quarter was $1.64, an increase of 18.0% over the prior year quarter. GAAP...

Continue reading

Castle Biosciences Reports Third Quarter 2025 Results

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2025. “We delivered a strong...

Continue reading

ThredUp Announces Third Quarter 2025 Results

All results reported are for continuing operations, unless otherwise noted.Record quarterly revenue of $82.2 million, representing an increase of 34% year-over-year Quarterly gross margin of 79.4% and an increase in gross profit of 34% year-over-year Active Buyers of 1.57 million, representing growth of 26% year-over-year, with new buyer growth of 54% year-over-year, reflecting ThredUp’s best quarter for new buyer acquisition in its history Ended the quarter with cash and cash equivalents, restricted cash, and marketable securities of $56.1 million, substantially consistent with the $56.2 million reported last quarter Issued a revised fourth quarter and full year 2025 financial outlook, raising revenue expectationsOAKLAND, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest...

Continue reading

EverQuote Announces Third Quarter 2025 Financial Results

Third Quarter Revenue Growth of 20% Year-Over-Year to $173.9 million Record Third Quarter Net Income up 63% Year-Over-Year to $18.9 million Record Adjusted EBITDA Increases 33% Year-Over-Year to $25.1 millionCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the third quarter ended September 30, 2025. “In the third quarter, we achieved record top and bottom line performance and we are making steady progress towards our vision of becoming the leading growth partner to P&C insurance providers,” said Jayme Mendal, CEO of EverQuote. “We are innovating new products, releasing features and further embedding AI into our marketplace to accelerate our transformation from a lead generation vendor to a multi-product, AI-powered...

Continue reading

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

HighlightsThird quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million. Entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) testing solution.SALT LAKE CITY, Nov. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic...

Continue reading

Superior Group of Companies Reports Third Quarter 2025 Results

– Total net sales of $138.5 million, compared to $149.7 million in prior year third quarter –– Net income of $2.7 million, compared to $5.4 million in prior year third quarter –– EBITDA of $7.5 million, compared to $11.7 million in prior year third quarter –– Board of Directors approves $0.14 per share quarterly dividend – ST. PETERSBURG, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its third quarter 2025 results. “Our earnings were as expected, demonstrating solid sequential progress from the second quarter and our updated full-year outlook reflects a higher mid-point,” said Michael Benstock, Chief Executive Officer. “We were also able to meaningfully improve SG&A, which bodes well for future profitability as greater economic clarity...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.